Preferably, the chemo-sensitizing nicotinic acetylcholine receptor (nAChR) antagonist is an a-9 acetylcholine receptor (nAChR) antagonist.
The compounds are useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7nAChR).
The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.
In still other embodiments, provided herein are methods for modulating a nicotinic acetylcholine receptor (nAChR).
The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.
Compositions which include a first α3β4 nicotinic receptor antagonist are also described.
The method includes administering to the patient a first α3β4 nicotinic receptor antagonist and administering to the patient a second α3β4 nicotinic receptor antagonist.
Alzheimer's: Nicotinic receptors as a new therapeutic target
Alzheimer's: nicotinic receptors as a new therapeutic target
Alzheimer’s: Nicotinic receptors as a new therapeutic target
An increase in phosphorylation of JAK2 indicates that the test substance stimulates the nicotine receptor, and wherein a decrease in phosphorylation of JAK2 indicates that the test substance inhibits the nicotine receptor.
The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
Varenicline is a partial agonist of the nicotine receptor.
The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
Alzheimer’s: Nicotinic receptors as a new therapeutic target
Alzheimer’s: Nicotinic receptors as a new therapeutic target
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists.
Representation in space of the nicotinic receptor. © Institut Pasteur
Alzheimer's: Nicotinic receptors as a new therapeutic target
The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine a7 receptor.
The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
Alzheimer’s: Nicotinic receptors as a new therapeutic target
Alzheimer's: Nicotinic receptors as a new therapeutic target
Alzheimer's: nicotinic receptors as a new therapeutic target
The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод